Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Resectable NSCLC × sintilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 55 Stomach Neoplasms 45 Carcinoma, Non-Small-Cell Lung 35 Colorectal Neoplasms 24 Esophageal Squamous Cell Carcinoma 19 Lung Neoplasms 11 Esophageal Neoplasms 11 Rectal Neoplasms 10 Nasopharyngeal Carcinoma 9 Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Pancreatic Neoplasms 7 Neoplasm Metastasis 6 Cholangiocarcinoma 6 Uterine Cervical Neoplasms 5 Small Cell Lung Carcinoma 5 Triple Negative Breast Neoplasms 4 Liver Neoplasms 4 Endometrial Neoplasms 4 Colonic Neoplasms 4 Carcinoma, Renal Cell 4 Recurrence 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Extranodal NK-T-Cell 3 Colorectal Cancer Metastatic 3 Carcinoma 3 Breast Neoplasms 3 Advanced Solid Tumors 3 Advanced Solid Tumor 3 Turcot syndrome 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡